Founded in 2011, icometrix (Leuven, Belgium; Boston, USA) strives for data-driven insights and personalized patient care, supported by artificial intelligence. icometrix offers a portfolio of eight regulatory-approved AI solutions to assist healthcare with various challenges; icobrain extracts data from brain MRI and CT scans for the radiological reporting and clinical management of neurological disorders such as multiple sclerosis, brain trauma, epilepsy, stroke, dementia, and Alzheimer's disease. icompanion, a digital platform, and mobile app helps people with MS and their care team to monitor clinical symptoms and treatments efficiently and objectively. In late 2023 icometrix achieved the issuance of new CPT codes (0865T/0866T) for AI-related brain MRI quantification software, by the American Medical Association, which marks a significant milestone and underscores the transformative impact of clinically meaningful and quantified brain MRI information on diagnostic and therapeutic decision-making. The new CPT codes have officially been activated as of January 1st, 2024. The novel reimbursement pathway is a game-changer for neuroradiology and neurology. Most recently the clinical validation of the icometrix icobrain aria software, to assist radiologists with the reading of amyloid-related imaging abnormalities (ARIA), was published in the JAMA. Today, icometrix is internationally active and connected to more than 500 clinical practices. In addition, icometrix supports pharmaceutical companies in phase I-III and Real-World Evidence (RWE) studies through imaging and data services, and digital health strategy.